PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. - Wikidata - wikimedia - TriplyDB

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.

http://www.wikidata.org/entity/Q36614270

about

New developments in the management of moderate-to-severe hemophilia B Polymer-drug conjugates: origins, progress to date and future directions Therapeutic angiogenesis: controlled delivery of angiogenic factors.PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development Advances in PEGylation of important biotech molecules: delivery aspects Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery Engineering of the E. coli outer membrane protein FhuA to overcome the hydrophobic mismatch in thick polymeric membranes The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Fundamentals of translational neuroscience in toxicologic pathology: optimizing the value of animal data for human risk assessment.Emerging PEGylated drugs.Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62.Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy Biodefunctionalization of functionalized single-walled carbon nanotubes in mice Inhibition of Staphylococcus epidermidis biofilms using polymerizable vancomycin derivatives.Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Developing Polyamine-Based Peptide Amphiphiles with Tunable Morphology and Physicochemical Properties.Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.Efficacy and tolerability of Laxatan Granulat in patients with chronic constipation PEG-like nanoprobes: multimodal, pharmacokinetically and optically tunable nanomaterials.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function Design of non-standard insulin analogs for the treatment of diabetes mellitus Poly[(ethylene oxide)-co-(methylene ethylene oxide)]: A hydrolytically-degradable poly(ethylene oxide) platform.Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates New treatments in hemophilia: insights for the clinician.Pre-existing Antibody: Biotherapeutic Modality-Based Review.A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector Polyamide Nanogels from Generally Recognized as Safe Components and Their Toxicity in Mouse Preimplantation Embryos.Designing degradable hydrogels for orthogonal control of cell microenvironments.Certolizumab pegol: a new biologic targeting rheumatoid arthritis.Product development issues for PEGylated proteins.Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.Organophosphorus hydrolase as an in vivo catalytic nerve agent bioscavenger.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.Bioresorbable adhesion barrier for reducing the severity of postoperative cardiac adhesions: Focus on REPEL-CV(®).PEGylated nanomedicines: recent progress and remaining concerns.

P2860

Q26751323-6CCDBE92-CB86-46A4-B7B7-028C5A3F3607 Q27002505-6C47D5B9-51DD-4B85-9F3E-6B1BDAA2BD7C Q27023731-ED31BD15-360F-4B2A-AFEC-3E192E181D68 Q27691352-DD64CAF3-F584-4044-89C9-36144DB99B7C Q28082880-3D815C56-DBCE-4749-A2D6-2DF9B427C8BA Q28277255-2069013D-D229-4B04-8A3A-FFFE8BC0FDA5 Q28396383-AB9CEE49-4038-45B4-9D69-44A59C725128 Q30155616-0BEB8A5D-5230-4F00-94EB-DEC42D1318DB Q30234616-D85A7DCD-DBD9-4013-8B49-6B39668215D5 Q30869945-43B75F2C-69A8-4BF5-8AD7-3396312B0C2A Q33447691-1D6B2AB5-5F13-4924-A8E2-F60E125889AA Q33552218-968032C5-2110-4865-A7CB-5DB947F20082 Q33769085-F20CA86B-4990-4ADD-AD8F-9023EAF40412 Q33824836-F715DCB6-C34F-4380-AEE0-F855539C3B1C Q33831343-69905C8B-1C15-432D-A7D3-13925ECFE3D7 Q33917599-0DEE3A31-2BB3-41D4-84E1-CAFB1EFFC834 Q33956388-63C12267-DA98-42CA-9590-A52098D906BA Q34001975-228B07BF-BAE0-4AA9-B36F-D9B0D6F24F36 Q34447986-1B61414A-64FB-4374-8771-7537A7045769 Q34556818-9E672009-2123-4284-8A6F-5C39D40F33D7 Q35004153-1F82DCB5-DA9B-4930-9EEB-97B96B4B2D6B Q35026317-2AFC258D-C68F-4EAE-B3FA-D6ED6E51F855 Q35159784-C044DA63-D760-4D84-A343-90E54D9D20F7 Q36039649-139B8D0D-5AF4-49AF-9790-C3C91BB2517F Q36072498-407AE0D2-2997-4636-A23A-3BCA7551FD06 Q36374363-E08F6877-49D2-4D9E-AF2F-1C118A56E66A Q36433148-0EBC5E99-CA90-4BF6-8B53-77266E4E56EE Q36533097-AC83EEF2-FAA6-4DCF-99FD-B2E67766452F Q36612681-D279AFC7-A793-4B67-B1E1-1E3C80100012 Q36653888-7043B781-9714-47A7-8D0B-B12169A2A50A Q36969493-1F7FB31E-84B7-4E1B-ACDA-DC6AF54F3EE0 Q37145696-8D847C00-7B0F-4B2C-9AAC-8BE86D23753B Q37146704-9078CDB7-CE79-4823-B625-B0C1F8CF981A Q37676988-F9B07B18-F506-40F9-AFE0-4789265B13CA Q37790702-08105199-ECF7-46D0-B47C-3CA910EA9B19 Q37939967-26889222-239F-472C-9E96-27CF4B6C507D Q37989116-C2C0FD46-5EEA-45FD-8BC8-E4332B5CD0E2 Q38036746-3BE3CE5C-4051-463E-8A29-58E436F81F05 Q38037070-860BF662-9F9E-4157-BE13-D9AE68549415 Q38167826-BF78F42A-4BD8-48D6-A8D6-04BCC3E501C0

P2860

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.

http://www.wikidata.org/entity/Q36614270

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

PEGylated proteins: evaluation ...... definitive metabolism studies.

@ast

PEGylated proteins: evaluation ...... definitive metabolism studies.

@en

type

label

PEGylated proteins: evaluation ...... definitive metabolism studies.

@ast

PEGylated proteins: evaluation ...... definitive metabolism studies.

@en

prefLabel

PEGylated proteins: evaluation ...... definitive metabolism studies.

@ast

PEGylated proteins: evaluation ...... definitive metabolism studies.

@en

P1433

Q36614270-C0DFE21D-D1DE-4CC3-A975-81EE33A54DAD

P1476

Q36614270-E99BC154-2E40-48D3-96D4-E18446DA5D4B

P2093

Q36614270-1E66DDDA-4217-4A2A-A28B-0A21AF6802A5

Q36614270-95AF75A9-0220-4CA5-B448-405BAD313ECE

Q36614270-AA9E0A18-09DC-47FA-B3BA-7B2C4C56DFA6

Q36614270-B0966A6B-436D-4CAB-9625-1FF8046997D3

Q36614270-D266118A-5DB7-4C59-A1F6-2D2BC87CA1EE

Q36614270-E317F275-BA34-478C-AE70-B97B128D251B

Q36614270-EB8608C8-E899-462C-A235-DDA6908E563F

P304

Q36614270-D5603977-BF1F-4C4E-8801-31320B8B47C4

P31

Q36614270-1BC180DA-532E-4DBD-A30D-5821A83FD209

P356

Q36614270-FFC882B4-9C88-45B8-B867-277C62B65600

P433

Q36614270-E1A4F371-3CA5-49AE-99D0-097E2BE31C85

P478

Q36614270-8E91AF07-FC5B-4030-A2B7-45941D12D2E1

P577

Q36614270-85E6701A-9633-494E-99E2-A3C849ED4C08

P5875

Q36614270-5E0CB430-EDA7-40DF-80D1-D682A471D940

P698

Q36614270-A0060DEB-88F9-40D3-9188-0D89C92C0BF5

P356

P1433

Drug Metabolism and Disposition

P1476

PEGylated proteins: evaluation ...... definitive metabolism studies.

@en

P2093

Dennis Smith

http://www.w3.org/2001/XMLSchema#string

Eric Didier

http://www.w3.org/2001/XMLSchema#string

Jeanne Stadler

http://www.w3.org/2001/XMLSchema#string

Lorraine Tilbury

http://www.w3.org/2001/XMLSchema#string

Ned Siegel

http://www.w3.org/2001/XMLSchema#string

Philip Harris

http://www.w3.org/2001/XMLSchema#string

Rob Webster

http://www.w3.org/2001/XMLSchema#string

P304

9-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.106.012419

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6774009

http://www.w3.org/2001/XMLSchema#string

P698

17020954

http://www.w3.org/2001/XMLSchema#string